BioNxt实验性癌症治疗在60%的早期试验参与者中收缩了肿瘤,没有重大安全问题。 BioNxt's experimental cancer treatment shrank tumors in 60% of early trial participants with no major safety issues.

BioNxt是一家生物技术公司,于2025年11月4日宣布,其实验性癌症治疗在早期临床试验中显示出令人乐观的结果,60%的参与者观察到肿瘤显著减少。 BioNxt, a biotechnology company, announced on November 4, 2025, that its experimental cancer treatment showed promising results in early clinical trials, with significant tumor reduction observed in 60% of participants. 该公司计划向林业发展局提交数据,以供加速核准,并在今年晚些时候启动第3阶段试验。 The company plans to submit data to the FDA for accelerated approval and initiate phase 3 trials later this year. 初步研究中未报告任何重大安全问题。 No major safety concerns were reported in the initial study.